Get access

Why could passive Immunoglobulin E antibody therapy be safe in clinical oncology?

Authors

  • E. Jensen-Jarolim,

    1. Institute of Pathophysiology and Allergy Research IPA, Center of Pathophysiology, Infectiology and Immunology, Medical University Vienna, Vienna, Austria
    Search for more papers by this author
  • J. Singer

    1. Institute of Pathophysiology and Allergy Research IPA, Center of Pathophysiology, Infectiology and Immunology, Medical University Vienna, Vienna, Austria
    Search for more papers by this author

  • This editorial discusses the findings of the paper in this issue by Rudman et al. [35] pp. 1400–1413.


Prof. Erika Jensen-Jarolim, MD, Inst. of Pathophysiology and Allergy Research, Center of Pathophysiology, Infectiology and Immunology, Medical University Vienna. E-mail: erika.jensen-jarolim@meduniwien.ac.at

Abstract

Cite this as: E. Jensen-Jarolim and J. Singer, Clinical & Experimental Allergy, 2011 (41) 1337–1340.

Ancillary